Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (ADAPT)

Cancer
Stefan Octavian Ciurea
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (ADAPT)
Hodgkin's Lymphoma
Leukemia other
Lymphoid Leukemia
Multiple Myeloma
Myeloid and Monocytic Leukemia
Non-Hodgkin's Lymphoma
Other Hematopoietic

Study Description

This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.

Eligibility

You can participate in this study if you satisfy the following criteria:

  • Are 18-70 years of age
  • Confirmed diagnosis of Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), Chronic Myeloid Leukemia (CML), Non-Hodgkin Lymphoma (NHL), Hodgkin Disease (HD), Chronic Lymphocytic Leukemia (CLL) requiring AHSCT

You cannot participate in this study if you have any of the following criteria:

  • Not able to comply with medical recommendations or follow-up procedures
  • Any active infection
  • Pregnant
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.